--- title: "Signature Estate & Investment Advisors LLC Reduces Holdings in Merck & Co., Inc. $MRK" description: "Signature Estate & Investment Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 27.5% in Q2, according to a recent SEC filing. After selling 3,058 shares, the firm now holds 8,069 shar" type: "news" locale: "en" url: "https://longbridge.com/en/news/262004212.md" published_at: "2025-10-21T08:29:02.000Z" --- # Signature Estate & Investment Advisors LLC Reduces Holdings in Merck & Co., Inc. $MRK > Signature Estate & Investment Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 27.5% in Q2, according to a recent SEC filing. After selling 3,058 shares, the firm now holds 8,069 shares valued at $639,000. Other hedge funds have also adjusted their positions in Merck. Analysts have set a consensus target price of $104.33 for the stock, which currently trades at $86.30, with a market cap of $215.56 billion and a PE ratio of 13.30. Signature Estate & Investment Advisors LLC trimmed its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 27.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,069 shares of the company's stock after selling 3,058 shares during the period. Signature Estate & Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $639,000 as of its most recent SEC filing. Get **Merck & Co., Inc.** alerts: - 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Several other hedge funds have also bought and sold shares of the business. Barnes Dennig Private Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the first quarter valued at approximately $27,000. Legend Financial Advisors Inc. bought a new position in shares of Merck & Co., Inc. during the second quarter valued at approximately $25,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company's stock valued at $34,000 after purchasing an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the first quarter valued at approximately $36,000. Finally, Fiduciary Wealth Partners LLC bought a new position in shares of Merck & Co., Inc. during the first quarter valued at approximately $48,000. Institutional investors own 76.07% of the company's stock. ## Analysts Set New Price Targets MRK has been the subject of a number of analyst reports. Wells Fargo & Company decreased their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Berenberg Bank cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and decreased their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a "neutral" rating and a $95.00 target price for the company. Finally, Morgan Stanley decreased their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of "Hold" and a consensus target price of $104.33. - 5 Healthcare Plays Powering the Sector’s Big Comeback **Read Our Latest Analysis on MRK** ## Merck & Co., Inc. Stock Performance Shares of MRK stock opened at $86.30 on Tuesday. The company has a 50 day moving average price of $84.03 and a 200-day moving average price of $81.35. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $109.17. The firm has a market capitalization of $215.56 billion, a PE ratio of 13.30, a P/E/G ratio of 0.93 and a beta of 0.37. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. - As the Market Rotates, This Healthcare ETF Is Leading the Way Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The firm had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year. ## About Merck & Co., Inc. (Free Report) Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. ## Read More - Five stocks we like better than Merck & Co., Inc. - How to Calculate Options Profits - Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet - Stock Market Upgrades: What Are They? - 3 High-Yield Banks for Investors to Buy on the Dip - How to Use High Beta Stocks to Maximize Your Investing Profits - 5 Surprising Stocks Set to Benefit From a Future Robotics Boom **Want to see what other hedge funds are holding MRK?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Merck & Co., Inc. Right Now? Before you consider Merck & Co., Inc., you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list. While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 默克｜8-K：2025 财年 Q4 营收 164 亿美元超过预期 | | [Link](https://longbridge.com/en/news/274647604.md) | | 默沙东 2025 全年营收 650 亿美元，同增 1%，26 年营收指引 655 亿至 670 亿美元，低于预期｜财报见闻 | 默沙东发布 2025 年财报，全年营收 650 亿美元，同比增长 1%。预计 2026 年营收指引为 655 亿至 670 亿美元，低于市场预期。每股收益为 8.98 美元，同比增长 17%。Gardasil 疫苗销售面临挑战，2025 年 | [Link](https://longbridge.com/en/news/274693917.md) | | 根据最近的 SEC 文件，默克公司的一位内部人士出售了价值 1,827,992 美元的股票 | 2026 年 2 月 6 日下午 4:30（东部标准时间）——约翰内斯·雅各布斯·奥斯图伊岑（Johannes Jacobus Oosthuizen），美国市场总裁，于 2026 年 2 月 6 日出售了 15,000 股默克公司（Merc | [Link](https://longbridge.com/en/news/275175518.md) | | 大摩表示，默克的产品线进展和业务发展战略仍然是关注的焦点 | 默克的产品线进展和业务发展战略仍然受到关注，摩根士丹利表示 | [Link](https://longbridge.com/en/news/274841608.md) | | Hardy Reed LLC 出售了 8,831 股默克公司（Merck & Co., Inc.）的股票 $MRK | Hardy Reed LLC 在第三季度减少了对默克公司（NYSE:MRK）的持股比例，降幅为 57.6%，出售了 8,831 股，目前持有 6,507 股，市值为 546,000 美元。其他机构投资者也调整了他们的持仓。内部人士的卖出包括 | [Link](https://longbridge.com/en/news/276002182.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.